Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266 · see citing works

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281 · see citing works

Detection of a SARS-CoV-2 variant of concern in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510 · see citing works

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992 · see citing works

Mapping the Antigenic and Genetic Evolution of Influenza Virus

Smith, D. J., Lapedes, A. S., de Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2004) · Science · doi:10.1126/science.1097211 · Cited by 1,868 · see citing works

SARS-CoV-2 productively infects human gut enterocytes

Lamers, M. M., Beumer, J., van der Vaart, J., Knoops, K., Puschhof, J., Breugem, T. I., Ravelli, R. B. G., Paul van Schayck, J., Mykytyn, A. Z., Duimel, H. Q., et al. (2020) · Science · doi:10.1126/science.abc1669 · Cited by 1,573 · see citing works

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature · doi:10.1038/s41586-021-04389-z · Cited by 1,514 · see citing works

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Mlcochova, P., Kemp, S. A., Dhar, M. S., Papa, G., Meng, B., Ferreira, I. A. T. M., Datir, R., Collier, D. A., Albecka, A., Singh, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03944-y · Cited by 1,337 · see citing works

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333 · see citing works

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Sia, S. F., Yan, L.-M., Chin, A. W. H., Fung, K., Choy, K.-T., Wong, A. Y. L., Kaewpreedee, P., Perera, R. A. P. M., Poon, L. L. M., Nicholls, J. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2342-5 · Cited by 1,303 · see citing works

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study

Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00017-4 · Cited by 1,041 · see citing works

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.046 · Cited by 930 · see citing works

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897 · see citing works

Animal models for COVID-19

Muñoz-Fontela, C., Dowling, W. E., Funnell, S. G. P., Gsell, P.-S., Riveros-Balta, A. X., Albrecht, R. A., Andersen, H., Baric, R. S., Carroll, M. W., Cavaleri, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2787-6 · Cited by 798 · see citing works

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021

Campbell, F., Archer, B. N., Laurenson‐Schafer, H., Jinnai, Y., Konings, F. A. J., Batra, N., Pavlin, B. I., Vandemaele, K., Kerkhove, M. D. V., Jombart, T., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.24.2100509 · Cited by 792 · see citing works

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697 · see citing works

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

Halfmann, P., Iida, S., Iwatsuki‐Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S. M., Darling, T. L., Joshi, A., Loeber, S. J., Singh, G., et al. (2022) · Nature · doi:10.1038/s41586-022-04441-6 · Cited by 654 · see citing works

A history of influenza.

Potter, C. W. (2001) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.2001.01492.x · Cited by 584 · see citing works

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

Rössler, A., Riepler, L., Bante, D., von Laer, D., & Kimpel, J. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119236 · Cited by 466 · see citing works

Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients

GeurtsvanKessel, C. H., Geers, D., Schmitz, K. S., Mykytyn, A. Z., Lamers, M. M., Bogers, S., Scherbeijn, S. M. J., Gommers, L., Sablerolles, R. S. G., Nieuwkoop, N. N., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo2202 · Cited by 401 · see citing works

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

Frampton, D., Rampling, T., Cross, A., Bailey, H., Heaney, J., Byott, M., Scott, R., Sconza, R., Price, J., Margaritis, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00170-5 · Cited by 387 · see citing works

The variant gambit: COVID-19’s next move

Plante, J. A., Mitchell, B. M., Plante, K. S., Debbink, K., Weaver, S. C., & Menachery, V. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.020 · Cited by 328 · see citing works

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants

Yu, J., Collier, A.-R. Y., Rowe, M., Mardas, F., Ventura, J. D., Wan, H., Miller, J., Powers, O. C., Chung, B., Siamatu, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2201849 · Cited by 322 · see citing works

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

Bruel, T., Hadjadj, J., Maes, P., Planas, D., Sève, A., Staropoli, I., Guivel‐Benhassine, F., Porrot, F., Bolland, W., Nguyen, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01792-5 · Cited by 273 · see citing works

Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

Funk, T., Pharris, A., Spiteri, G., Bundle, N., Melidou, A., Carr, M. J., González, G., Leon, A. A. G., Crispie, F., O’Connor, L., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.16.2100348 · Cited by 246 · see citing works

The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern

Lin, L., Liu, Y., Tang, X., & He, D. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.775224 · Cited by 228 · see citing works

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum

Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.-A., Kaneda, A., Nakagawa, S., & Sato, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2114706 · Cited by 214 · see citing works

Milder disease with Omicron: is it the virus or the pre-existing immunity?

Sigal, A. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00678-4 · Cited by 153 · see citing works

SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site

Mykytyn, A. Z., Breugem, T. I., Riesebosch, S., Schipper, D., van den Doel, P. B., Rottier, R. J., Lamers, M. M., & Haagmans, B. L. (2021) · eLife · doi:10.7554/elife.64508 · Cited by 150 · see citing works

Mapping SARS-CoV-2 antigenic relationships and serological responses

Wilks, S. H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Corman, V. M., Daniell, X. G., et al. (2023) · Science · doi:10.1126/science.adj0070 · Cited by 134 · see citing works

The Geometry of Shape Space: Application to Influenza

Lapedes, A. S., & Farber, R. (2001) · Journal of Theoretical Biology · doi:10.1006/jtbi.2001.2347 · Cited by 118 · see citing works

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3

Arora, P., Zhang, L., Rocha, C., Sidarovich, A., Kempf, A. M., Schulz, S. R., Cossmann, A., Manger, B., Baier, E., Tampe, B., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00224-9 · Cited by 94 · see citing works

Use of Antigenic Cartography in Vaccine Seed Strain Selection

Fouchier, R. A. M., & Smith, D. J. (2010) · Avian Diseases · doi:10.1637/8740-032509-resnote.1 · Cited by 63 · see citing works

Mapping SARS-CoV-2 antigenic relationships and serological responsesPreprint

Wilks, S., Mühlemann, B., Shen, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.28.477987 · Cited by 59 · see citing works

SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epitheliumPreprint

Lamers, M. M., Mykytyn, A. Z., Breugem, T. I., Gröen, N., Knoops, K., Schipper, D., van Acker, R., van den Doel, P. B., Bestebroer, T. M., Koopman, C. D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.19.476898 · Cited by 47 · see citing works

Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 –May 2021

Veneti, L., Seppälä, E. M., Storm, M. L., Salamanca, B. V., Buanes, E. A., Aasand, N., Naseer, U., Bragstad, K., Hungnes, O., Bøås, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258513 · Cited by 46 · see citing works

Mapping SARS-CoV-2 antigenic relationships and serological responses

Wilks, S. H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Corman, V. M., Daniell, X. G., et al. (2023) · Science · doi:10.1126/science.adj0070 · Cited by 134 · see citing works

Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity

Aguilar-Bretones, M., Fouchier, R. A. M., Koopmans, M., & van Nierop, G. P. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162192 · Cited by 104 · see citing works

Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron

van der Straten, K., Guerra, D., van Gils, M. J., Bontjer, I., Caniels, T. G., van Willigen, H. D. G., Wynberg, E., Poniman, M., Burger, J. A., Bouhuijs, J. H., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.018 · Cited by 120 · see citing works

Population immunity predicts evolutionary trajectories of SARS-CoV-2

Meijers, M., Ruchnewitz, D., Eberhardt, J., Łuksza, M., & Lässig, M. (2023) · Cell · doi:10.1016/j.cell.2023.09.022 · Cited by 97 · see citing works

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Rössler, A., Netzl, A., Knabl, L., Schäfer, H., Wilks, S., Bante, D., Falkensammer, B., Borena, W., von Laer, D., Smith, D. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35312-3 · Cited by 77 · see citing works

Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity

van Leeuwen, L. P. M., GeurtsvanKessel, C. H., Ellerbroek, P. M., de Bree, G. J., Potjewijd, J., Rutgers, A., Jolink, H., van de Veerdonk, F. L., Gorp, E. C. M. V., de Wilt, F., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.04.002 · Cited by 68 · see citing works

Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history

Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R. A., Coggins, S. A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.012 · Cited by 59 · see citing works

Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R., Coggins, S., et al. (2022) · doi:10.1101/2022.07.05.498883 · Cited by 68 · see citing works

Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1

Mykytyn, A. Z., Rosu, M. E., Kok, A., Rissmann, M., van Amerongen, G., GeurtsvanKessel, C. H., de Vries, R. D., Munnink, B. B. O., Smith, D. J., Koopmans, M., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00384-6 · Cited by 65 · see citing works

Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature

Cantoni, D. M., Wilkie, C., Bentley, E. M., Neto, M. M., Wright, E., Scott, S. D., Ray, S., Castillo‐Olivares, J., Heeney, J. L., Mattiuzzo, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1184362 · Cited by 56 · see citing works

SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models

Mykytyn, A. Z., Breugem, T. I., Geurts, M. H., Beumer, J., Schipper, D., van Acker, R., van den Doel, P. B., van Royen, M. E., Zhang, J., Clevers, H. C., et al. (2023) · Journal of Virology · doi:10.1128/jvi.00851-23 · Cited by 58 · see citing works

Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques

Rosenke, K., Lewis, M. C., Feldmann, F., Bohrnsen, E., Schwarz, B. H., Okumura, A., Bohler, F., Callison, J. A., Shaia, C., Bosio, C. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.166485 · Cited by 46 · see citing works

When to update COVID-19 vaccine composition

Grant, R., Sacks, J. A., Abraham, P., Chunsuttiwat, S., Cohen, C., Figueroa, J. P., Fleming, T. R., Fine, P., Goldblatt, D., Hasegawa, H., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02220-y · Cited by 47 · see citing works

Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa

Sun, K., Tempia, S., Kleynhans, J., von Gottberg, A., McMorrow, M. L., Wolter, N., Bhiman, J. N., Moyes, J., Carrim, M., Martinson, N. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35652-0 · Cited by 45 · see citing works

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography

Rössler, A., Netzl, A., Knabl, L., Bante, D., Wilks, S. H., Borena, W., von Laer, D., Smith, D. J., & Kimpel, J. (2023) · Nature Communications · doi:10.1038/s41467-023-41049-4 · Cited by 45 · see citing works

Distinctive serotypes of SARS-related coronaviruses defined by convalescent sera from unvaccinated individuals

Tan, C. W., Zhu, F., Chia, W. N., Young, B. E., Yeoh, A. Y.-Y., Althaus, T., Yung, C. F., Yap, W. C., Lim, B. L., Chen, M. I.-C., et al. (2023) · hLife · doi:10.1016/j.hlife.2023.07.002 · Cited by 42 · see citing works

Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccinesPreprint

Bowen, J. E., Sprouse, K. R., Walls, A. C., Mazzitelli, I. G., Logue, J. K., Franko, N., Ahmed, K., Ansari, A. S., Cameroni, E., Gori, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.15.484542 · Cited by 38 · see citing works

Classification of five SARS-CoV-2 serotypes based on RBD antigenicities

Hu, S., Wu, C., Wu, X., Ma, X., Shu, C., Chen, Q., Zheng, A., Yang, H., Lü, J., Du, P., et al. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.09.048 · Cited by 40 · see citing works

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 34 · see citing works

Antigenic evolution of SARS coronavirus 2

Mykytyn, A. Z., Fouchier, R. A. M., & Haagmans, B. L. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101349 · Cited by 36 · see citing works

Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial

Tan, N. H., Geers, D., Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Bogers, S., van Dijk, L. L. A., Gommers, L., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00140-8 · Cited by 37 · see citing works

Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections

Medits, I., Springer, D. N., Graninger, M., Camp, J. V., Höltl, E., Aberle, S. W., Traugott, M. T., Hoepler, W., Deutsch, J., Lammel, O., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.946318 · Cited by 36 · see citing works

Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant

Springer, D. N., Perkmann, T., Jani, C. M., Mucher, P., Prüger, K., Marculescu, R., Reuberger, E., Camp, J. V., Graninger, M., Borsodi, C., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02129-22 · Cited by 34 · see citing works

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice

Muik, A., Lui, B. G., Bacher, M., Wallisch, A.-K., Toker, A., Cadima-Couto, Í., Güler, A., Mampilli, V., Schmitt, G. J., Mottl, J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.ade9888 · Cited by 36 · see citing works

SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022

Cheng, S. M., Mok, C. K. P., Chan, K. C., Ng, S. S., Lam, B. H., Luk, L. L., Ko, F. W., Chen, C., Yiu, K., Li, J. K., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.18.2200178 · Cited by 31 · see citing works

Immune Evasion of SARS-CoV-2 Omicron Subvariants

Ke, H., Chang, M., & Marasco, W. A. (2022) · Vaccines · doi:10.3390/vaccines10091545 · Cited by 29 · see citing works

Electrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era

Fantini, J., Azzaz, F., Chahinian, H., & Yahi, N. (2023) · Viruses · doi:10.3390/v15020284 · Cited by 29 · see citing works

Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein

Zhang, J., Tang, W., Gao, H., Lavine, C. L., Shi, W. K., Peng, H., Zhu, H., Anand, K., Kosikova, M., Kwon, H. J., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01023-6 · Cited by 28 · see citing works

Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong

Leung, D., Duque, J. S. R., Yip, K. M., So, H., Wong, W. H. S., & Lau, Y. (2023) · Communications Medicine · doi:10.1038/s43856-022-00233-1 · Cited by 28 · see citing works

Evolution of Omicron lineage towards increased fitness in the upper respiratory tract in the absence of severe lung pathology

Wickenhagen, A., Flagg, M., Port, J. R., Yinda, C. K., Goldin, K., Gallogly, S., Schulz, J. E., Lutterman, T. R., Williamson, B. N., Kaiser, F. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55938-3 · Cited by 28 · see citing works

Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD

Li, Q., Zhang, M., Liang, Z., Zhang, L., Wu, X., Yang, C., An, Y., Tong, J., Liu, S., Li, T., et al. (2022) · MedComm · doi:10.1002/mco2.130 · Cited by 26 · see citing works

An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution

Subissi, L., Otieno, J. R., Worp, N., Cohen, H. A., Munnink, B. B. O., Abu-Raddad, L. J., Alm, E., Barakat, A., Barclay, W., Bhiman, J. N., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02949-0 · Cited by 25 · see citing works

Antigenic distance between primary and secondary dengue infections correlates with disease risk

Wang, L., Huang, A. T., Katzelnick, L. C., Lefrancq, N., Escoto, A. C., Duret, L., Chowdhury, N., Jarman, R. G., Conte, M. A., Berry, I. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3259 · Cited by 25 · see citing works

Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study

Hogan, A. B., Wu, S. L., Toor, J., Mesa, D. O., Doohan, P., Watson, O. J., Winskill, P., Charles, G. D., Barnsley, G., Riley, E. M., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004195 · Cited by 27 · see citing works

Combining antigenic data from public sources gives an early indication of the immune escape of emerging virus variantsPreprint

Netzl, A., Türeli, S., LeGresley, E. B., Mühlemann, B., Wilks, S., & Smith, D. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.31.474032 · Cited by 25 · see citing works

Omicron BA.2 Lineage, the “Stealth” Variant: Is It Truly a Silent Epidemic? A Literature Review

Tiecco, G., Storti, S., Arsuffi, S., Degli-Antoni, M., Focà, E., Castelli, F., & Quiros-Roldan, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137315 · Cited by 21 · see citing works

Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era

Pather, S., Muik, A., Rizzi, R., & Mensa, F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2232851 · Cited by 23 · see citing works

Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression

Petráš, M., Máčalík, R., Janovská, D., Čelko, A. M., Dáňová, J., Selinger, E., Doleček, J., Neradová, S., Franklová, M., Dlouhý, P., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02663-z · Cited by 21 · see citing works

Antigenic cartography using variant-specific hamster sera reveals substantial antigenic variation among Omicron subvariants

Mühlemann, B., Trimpert, J., Walper, F., Schmidt, M. L., Jansen, J., Schroeder, S., Jeworowski, L. M., Beheim-Schwarzbach, J., Bleicker, T., Niemeyer, D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2310917121 · Cited by 19 · see citing works

Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Zaeck, L. M., Tan, N. H., Rietdijk, W. J. R., Geers, D., Sablerolles, R. S. G., Bogers, S., van Dijk, L. L. A., Gommers, L., van Leeuwen, L. P. M., Rugebregt, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48414-x · Cited by 18 · see citing works

Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials

Yang, H. J., Hong, W., Shi, H., He, C., Hong, L., Zhou, Y., Yang, H., Alu, A., Chen, Z., Yang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55087-z · Cited by 18 · see citing works

COVID-19 vaccines versus pediatric hospitalization

Duque, J. S. R., Leung, D., Yip, K. M., Lee, D. H., So, H., Wong, W. H. S., & Lau, Y. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100936 · Cited by 17 · see citing works

SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies

Beukenhorst, A. L., Koch, C. M., Hadjichrysanthou, C., Alter, G., de Wolf, F., Anderson, R. M., & Goudsmit, J. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-00965-x · Cited by 17 · see citing works

Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses

Kassardjian, A., Sun, E., Sookhoo, J. R. V., Muthuraman, K., Boligan, K. F., Kucharska, I., Rujas, E., Jetha, A., Branch, D. R., Babiuk, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112391 · Cited by 17 · see citing works

Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants

Neerukonda, S. N., Wang, R., Vassell, R. A., Baha, H., Lusvarghi, S., Liu, S., Wang, T. T., Weiss, C. D., & Wang, W. (2022) · Journal of Virology · doi:10.1128/jvi.01140-22 · Cited by 17 · see citing works

Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine

Debes, A. K., Xiao, S., Egbert, E. R., Caturegli, P., Gadala, A., Colantuoni, E., Sitaras, I., Pekosz, A. S., & Milstone, A. M. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02046-22 · Cited by 16 · see citing works

Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization

Miyamoto, S., Arashiro, T., Ueno, A., Kanno, T., Saito, S., Katano, H., Iida, S., Ainai, A., Ozono, S., Hemmi, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.105969 · Cited by 13 · see citing works

Ultra-sensitive and specific detection of pathogenic nucleic acids using composite-excited hyperfine plasma spectroscopy combs sensitized by Au nanoarrays functionalized with 2D Ta2C-MXene

Yang, W., Liu, R., Yan, J. R., Xie, Y., Wang, C., Jiang, M., Li, P., & Du, L. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115358 · Cited by 16 · see citing works

SARS-CoV-2 variant of concern fitness and adaptation in primary human airway epithelia

Meganck, R. M., Edwards, C. E., Mallory, M. L., Lee, R. E., Dang, H., Bailey, A. B., Wykoff, J. A., Gallant, S. C., Zhu, D. R., Yount, B. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114076 · Cited by 16 · see citing works

Is the time right for systematically serotyping SARS-related coronaviruses?

Tan, C. W., & Wang, L. (2024) · hLife · doi:10.1016/j.hlife.2023.12.007 · Cited by 16 · see citing works

Impact of hybrid immunity booster vaccination and Omicron breakthrough infection on SARS-CoV-2 VOCs cross-neutralization

Pradenas, E., Marfil, S., Urrea, V., Trigueros, M., Pidkova, T., Pons-Grífols, A., Ortiz, R., Rovirosa, C., Tarrés-Freixas, F., Aguilar‐Gurrieri, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106457 · Cited by 15 · see citing works

Omicron breakthrough infections in vaccinated or previously infected hamsters

Zhou, J., Sukhova, K., McKay, P. F., Kurshan, A., Yau, Y., Lechmere, T., Brown, J. C., Moshe, M., Kugathasan, R., Snell, L. B., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308655120 · Cited by 14 · see citing works

Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub

Jung, S.-M., Loo, S. L., Howerton, E., Contamin, L., Smith, C. P., Carcelén, E. C., Yan, K., Bents, S. J., Levander, J. D., Espino, J. U., et al. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004387 · Cited by 15 · see citing works

Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays

Mühlemann, B., Wilks, S. H., Baracco, L., Bekliz, M., Carreño, J. M., Corman, V. M., Davis-Gardner, M. E., Dejnirattisai, W., Diamond, M., Douek, D. C., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adl1722 · Cited by 18 · see citing works

SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies

Guo, H., Ha, S., Botten, J., Xu, K. Y., Zhang, N., An, Z., Strohl, W. R., Shiver, J. W., & Fu, T. (2024) · Viruses · doi:10.3390/v16050697 · Cited by 14 · see citing works

Safety, immunogenicity, and preliminary efficacy of a randomized clinical trial of omicron XBB.1.5-containing bivalent mRNA vaccine

Yu, X., Yang, W. J., Li, W., Wan, N., Yan, G., Zhou, Z., Zhu, X. M., Su, W., Li, Y., Xing, C., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.01.005 · Cited by 13 · see citing works

SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion

Ruan, W., Gao, P., Qu, X., Jiang, J., Zhao, Z., Qiao, S., Zhang, H., Yang, T., Li, D., Du, P., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105634 · Cited by 13 · see citing works

Ultra-sensitive specific detection of nucleic acids in pathogenic infections by Ta2C-MXene sensitization-based ultrafine plasmon spectroscopy combs

Yang, W., Yan, J. R., Liu, R., Xie, Y., Wang, C., Kou, Z., Li, P., & Jiang, M. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133785 · Cited by 12 · see citing works

Revolutionizing SARS-CoV-2 omicron variant detection: Towards faster and more reliable methods.

Li, D., Sun, C., Zhuang, P.-F., & Mei, X. (2023) · Talanta: The International Journal of Pure and Applied Analytical Chemistry · doi:10.1016/j.talanta.2023.124937 · Cited by 7 · see citing works

Exploring the Role of Antiviral Nasal Sprays in the Control of Emerging Respiratory Infections in the Community

Hadjichrysanthou, C., Beukenhorst, A. L., Koch, C. M., Alter, G., Goudsmit, J., Anderson, R. M., & de Wolf, F. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00710-z · Cited by 12 · see citing works

Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination

Geers, D., Sablerolles, R. S. G., van Baarle, D., Kootstra, N. A., Rietdijk, W. J. R., Schmitz, K. S., Gommers, L., Bogers, S., Nieuwkoop, N. J., van Dijk, L. L. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105753 · Cited by 12 · see citing works

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination

Cheng, S. M. S., Mok, C. K. P., Li, J. K. C., Chan, K. P., Luk, K. S., Lee, B. H. W., Gu, H., Chan, K., Tsang, L. C. H., Yiu, K. Y. S., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02335-9 · Cited by 12 · see citing works

Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan

Chao, C.-H., Cheng, D., Huang, S., Chuang, Y., Yeh, T., & Wang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023943 · Cited by 11 · see citing works

Omicron infection increases IgG binding to spike protein of predecessor variants

Mahalingam, G., Periyasami, Y., Arjunan, P., Subaschandrabose, R. K., Mathivanan, T. V., Mathew, R. S., Devi, R., Premkumar, P. S., Muliyil, J., Srivastava, A., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28419 · Cited by 11 · see citing works

Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron

Schröder, S., Richter, A. M., Veith, T., Emanuel, J., Gudermann, L., Friedmann, K., Jeworowski, L. M., Mühlemann, B., Jones, T. C., Müller, M. A., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02154-4 · Cited by 9 · see citing works

Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1

Wang, W., Bhushan, G. L., Paz, S., Stauft, C. B., Selvaraj, P., Goguet, E., Bishop‐Lilly, K. A., Subramanian, R., Vassell, R. A., Lusvarghi, S., et al. (2024) · Journal of Virology · doi:10.1128/jvi.00948-24 · Cited by 10 · see citing works

Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections

Suntronwong, N., Kanokudom, S., Duangchinda, T., Chantima, W., Pakchotanon, P., Klinfueng, S., Puenpa, J., Thatsanathorn, T., Wanlapakorn, N., & Poovorawan, Y. (2025) · Scientific Reports · doi:10.1038/s41598-024-84138-0 · Cited by 10 · see citing works

Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents

Coombes, N. S., Bewley, K. R., Duff, Y. L., Hurley, M., Smith, L. J., Weldon, T. M., Osman, K. L., Pullan, S. T., Berry, N. J., Hallis, B., et al. (2023) · Viruses · doi:10.3390/v15030633 · Cited by 10 · see citing works

Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters

Port, J. R., Yinda, C. K., Riopelle, J. C., Weishampel, Z. A., Saturday, T. A., Avanzato, V. A., Schulz, J. E., Holbrook, M. G., Barbian, K., Perry-Gottschalk, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42346-8 · Cited by 13 · see citing works

A chimeric adenovirus‐vectored vaccine based on Beta spike and Delta RBD confers a broad‐spectrum neutralization against Omicron‐included SARS‐CoV‐2 variants

Hong, W., Hong, L., Peng, D., Huang, Y., He, C., Yang, H. J., Zhou, Y., Liu, J., Pan, X., Que, H., et al. (2024) · MedComm · doi:10.1002/mco2.539 · Cited by 10 · see citing works

Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2

Resch, M. D., Wen, K., Mazboudi, R., Maasz, H. M., Persaud, M., Garvey, K., Gallardo, L., Gottlieb, P., Alimova, A., Khayat, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10121997 · Cited by 10 · see citing works

Neutralizing Immunity Induced Against the Omicron BA.1 and BA.2 Variants in Vaccine Breakthrough Infections

Brazer, N., Morris, M. K., Servellita, V., Anglin, K., Saldhi, P., Garcia-Knight, M., Bethancourt, S., Sotomayor-González, A., Wang, B., Foresythe, A., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac384 · Cited by 9 · see citing works

SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity

Aguilar-Bretones, M., den Hartog, Y., van Dijk, L. L. A., Malahe, S. R. K., Dieterich, M., Mora, H. T., Mueller, Y. M., Koopmans, M., Reinders, M. E. J., Baan, C. C., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00886-0 · Cited by 8 · see citing works

Longitudinal effects of SARS-CoV-2 breakthrough infection on imprinting of neutralizing antibody responses

Einhauser, S., Asam, C., Weps, M., Senninger, A., Peterhoff, D., Bauernfeind, S., Asbach, B., Carnell, G., Heeney, J. L., Wytopil, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105438 · Cited by 9 · see citing works

Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice

(2022) · doi:10.3390/v14040800 · Cited by 9 · see citing works

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol

Tan, N. H., Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Bogers, S., Geers, D., Zaeck, L. M., Koopmans, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1067749 · Cited by 9 · see citing works

Th1-dominant cytokine responses in kidney patients after COVID-19 vaccination are associated with poor humoral responses

den Hartog, Y., Malahe, S. R. K., Rietdijk, W. J. R., Dieterich, M., Gommers, L., Geers, D., Bogers, S., van Baarle, D., Diavatopoulos, D. A., Messchendorp, A. L., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00664-4 · Cited by 9 · see citing works

Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2

Francis, M. E., Jansen, E. B., Yourkowski, A., Selim, A., Swan, C. L., MacPhee, B. K., Thivierge, B. M., Buchanan, R. M., Lavender, K. J., Darbellay, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41761-1 · Cited by 10 · see citing works

Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant

Błaszczuk, A., Michalski, A., Sikora, D., Malm, M., Drop, B., & Polz-Dacewicz, M. (2022) · Vaccines · doi:10.3390/vaccines10101728 · Cited by 10 · see citing works

Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters

Shiwa-Sudo, N., Sakai, Y., Iwata‐Yoshikawa, N., Watanabe, S., Yamada, S., Kuroda, Y., Yamamoto, T., Shirakura, M., Fujisaki, S., Miyazaki, K., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01366-22 · Cited by 9 · see citing works

Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies

Zendt, M., Carrillo, F. A. B., Kelly, S., Saturday, T. A., DeGrange, M., Ginigeme, A., Wu, L., Callier, V., Ortega‐Villa, A. M., Faust, M. T., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh3150 · Cited by 11 · see citing works

Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera

Rössler, A., Netzl, A., Knabl, L., Wilks, S., Mühlemann, B., Türeli, S., Mykytyn, A. Z., von Laer, D., Haagmans, B. L., Smith, D. J., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00888-y · Cited by 9 · see citing works

Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination

Astakhova, E. A., Morozov, A. A., Byazrova, M. G., Sukhova, M. M., Mikhailov, A. A., Minnegalieva, A. R., Gorchakov, A. A., & Filatov, A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310493 · Cited by 8 · see citing works

A Multivariant Surrogate Neutralization Assay Identifies Variant-Specific Neutralizing Antibody Profiles in Primary SARS-CoV-2 Omicron Infection

Springer, D. N., Traugott, M. T., Reuberger, E., Kothbauer, K. B., Borsodi, C., Naegeli, M., Oelschlägel, T., Kelani, H., Lammel, O., Deutsch, J., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13132278 · Cited by 8 · see citing works

A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories

Brangel, P., Türeli, S., Mühlemann, B., Liechti, N., Zysset, D., Engler, O. B., Hunger‐Glaser, I., Ghiga, I., Mattiuzzo, G., Eckerle, I., et al. (2024) · Viruses · doi:10.3390/v16121936 · Cited by 8 · see citing works

Rapid and Sensitive Screening of Trace Infectious Disease Nucleic Acids Using a High-Density Surface Modified AuNPs@Ta 2 C-MXene/Au/TFBG Sensor

Yan, J. R., Yang, W., Liu, R., Xie, Y., Jiang, S., Li, P., Wang, C., Sui, Q., Liu, T., & Jiang, M. (2023) · Journal of Lightwave Technology · doi:10.1109/jlt.2023.3338849 · Cited by 7 · see citing works

Safety and immunogenicity of an adjuvanted recombinant spike protein‐based severe acute respiratory syndrome coronavirus 2 ( SARS‐CoV ‐2) vaccine, SpikeVet ™, in selected Carnivora, Primates and Artiodactyla in Australian zoos

McLelland, D. J., Lynch, M., Vogelnest, L., Eden, P. A., Wallace, A. M., Weller, J., Young, S., Vaughan‐Higgins, R., Antipov, A., Honda‐Okubo, Y., et al. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13429 · Cited by 7 · see citing works

A quadri-fluorescence SARS-CoV-2 pseudovirus system for efficient antigenic characterization of multiple circulating variants

Chen, J., Huang, Z., Xiao, J., Du, S., Bu, Q., Guo, H., Ye, J., Chen, S., Gao, J., Li, Z., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100856 · Cited by 7 · see citing works

Managing sources of error during pandemics

Cauchemez, S., Bosetti, P., & Cowling, B. J. (2023) · Science · doi:10.1126/science.add3173 · Cited by 7 · see citing works

Breakthrough infections by SARS-CoV-2 variants boost cross-reactive hybrid immune responses in mRNA-vaccinated Golden Syrian hamsters

Diego, J. G.-B., Singh, G., Jangra, S., Handrejk, K., Laporte, M., Chang, L. A., Zahed, S. S. E., Pache, L., Chang, M. W., Warang, P., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011805 · Cited by 8 · see citing works

Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost

Nair, M. S., Ribeiro, R. M., Wang, M., Bowen, A. D., Liu, L., Guo, Y., Chang, J. Y., Wang, P., Sheng, Z., Sobieszczyk, M. E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106345 · Cited by 5 · see citing works

Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamstersPreprint

Port, J. R., Yinda, C. K., Riopelle, J. C., Weishampel, Z. A., Saturday, T. A., Avanzato, V. A., Schulz, J. E., Holbrook, M. G., Barbian, K., Perry-Gottschalk, R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.29.502072 · Cited by 6 · see citing works

Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster seraPreprint

Wang, W., Bhushan, G. L., Paz, S., Stauft, C. B., Selvaraj, P., Goguet, E., Bishop‐Lilly, K. A., Subramanian, R., Vassell, R. A., Lusvarghi, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.05.588359 · Cited by 6 · see citing works

Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies

Marvelde, M. R. T., Mykytyn, A. Z., Kroeze, E. J. B. V., Bouffier, A., van Eck—Schipper, D., van den Doel, P., Handrejk, K., Koel, B. F., Rissmann, M., & Haagmans, B. L. (2026) · npj Vaccines · doi:10.1038/s41541-025-01348-x · Cited by 6 · see citing works

Mapping antibody footprints using binding profiles

Azulay, A., Cohen-Lavi, L., Friedman, L. M., McGargill, M. A., & Hertz, T. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100566 · Cited by 5 · see citing works

Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers

Oyebanji, O. A., Sundheimer, N., Ragavapuram, V., Wilson, B. M., Abul, Y., Gravenstein, S., Bosch, J., King, C. L., & Canaday, D. H. (2024) · GeroScience · doi:10.1007/s11357-024-01215-y · Cited by 5 · see citing works

Resistance to SARS-CoV-2 infection in camelid nasal organoids is associated with lack of ACE2 expression

Breugem, T. I., Riesebosch, S., Schipper, D., Mykytyn, A. Z., van den Doel, P., Segalés, J., Lamers, M. M., & Haagmans, B. L. (2024) · npj Viruses · doi:10.1038/s44298-024-00054-0 · Cited by 6 · see citing works

Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination

Jia, T., Wang, F., Chen, Y., Liao, G., Xu, Q., Chen, J., Wu, J., Li, N., Wang, L., Yuan, L., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106362 · Cited by 7 · see citing works

Population-based screening in a municipality after a primary school outbreak of the SARS-CoV-2 Alpha variant, the Netherlands, December 2020–February 2021

van Beek, J., Teesing, G. R., Munnink, B. B. O., Meima, A., Vriend, H. J., Elzakkers, J., de Graaf, M., Langeveld, J., Medema, G. J., Molenkamp, R., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276696 · Cited by 5 · see citing works

Exploring geometry of genome space via Grassmann manifolds

Li, X., Zhou, T., Feng, X., Yau, S., & Yau, S. S. ‐. (2024) · The Innovation · doi:10.1016/j.xinn.2024.100677 · Cited by 6 · see citing works

Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variantsPreprint

Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F. D., Bestebroer, T. M., de Wit, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.23.481644 · Cited by 43 · see citing works

Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1

Mykytyn, A. Z., Rosu, M. E., Kok, A., Rissmann, M., van Amerongen, G., GeurtsvanKessel, C. H., de Vries, R. D., Munnink, B. B. O., Smith, D. J., Koopmans, M., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00384-6 · Cited by 65 · see citing works

Antigenic Map of SARS-CoV-2 Variants Including OmicronPreprint

Furuse, Y. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3995729

Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron

van der Straten, K., Guerra, D., van Gils, M. J., Bontjer, I., Caniels, T. G., van Willigen, H. D. G., Wynberg, E., Poniman, M., Burger, J. A., Bouhuijs, J. H., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.018 · Cited by 120 · see citing works

Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination

Astakhova, E. A., Morozov, A. A., Byazrova, M. G., Sukhova, M. M., Mikhailov, A. A., Minnegalieva, A. R., Gorchakov, A. A., & Filatov, A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310493 · Cited by 8 · see citing works